Europe Pharma News

US–Swiss Tariff Cap Impact on Pharma: How the New US–Swiss Tariff Cap Shapes Pharma and Health Security

ipharmaservices

20 hours ago

EU clears Dupixent as first targeted CSU therapy in over a decade | iPharmaCenter

ipharmaservices

3 days ago

BMS' Breyanzi CAR-T Therapy Approved for Treating Mantle Cell Lymphoma | iPharmaCenter

ipharmaservices

Nov 25

European Drug Approvals | CHMP Positive Opinions | January 2025 | iPharmaCenter

ipharmaservices

Feb 3

Rybrevant plus Lazcluze approved in Europe for EGFR-NSCLC; showed improvement over Tagrisso | iPharmaCenter

ipharmaservices

Jan 2

Novartis’ Kisqali Gains European Commission Approval for Broader Use in Early Breast Cancer Patients at High Risk of Recurrence | iPharmaCenter

ipharmaservices

Dec 1, 2024

EMA Drug Approvals 2024 | CHMP Positive Opinion | October 2024 | iPharmaCenter

ipharmaservices

Oct 19, 2024

European Commission Greenlights Keytruda and Padcev Combo as First-Line Treatment for Advanced Urothelial Carcinoma | iPharmaCenter

ipharmaservices

Sep 3, 2024

European Commission Expands Approval for GSK's Arexvy, the First RSV Vaccine for Adults Aged 50-59 at Increased Risk | iPharmaCenter

ipharmaservices

Sep 1, 2024

Roche aims PNH market with SC PiaSky, aims to target AZ's Ultomiris market | iPharmaCenter

ipharmaservices

Aug 29, 2024

European Union Approves Ordspono for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | iPharmaCenter

ipharmaservices

Aug 27, 2024

Leqembi (lecanemab) Approved in Great Britain for Early-Stage Alzheimer's Disease | iPharmaCenter

ipharmaservices

Aug 24, 2024

The European Commission Grants Approval for Tepkinly for a New Indication in Treating Relapsed/Refractory Follicular Lymphoma in Adults | iPharmaCenter

ipharmaservices

Aug 24, 2024

Dupixent (Dupilumab) Gains EU Approval as the First Targeted Therapy for COPD

ipharmaservices

Jul 4, 2024

Committee for Medicinal Products for Human Use | CHMP Positive Opinion | June | Europe Drug Approvals | 2024 | iPharmaCenter

ipharmaservices

Jul 2, 2024

European Commission Approves Roche's Alecensa as First Targeted Adjuvant Therapy for Early-Stage ALK-Positive Lung Cancer | 2024 | iPharmaCenter

ipharmaservices

Jun 10, 2024

Biogen Gains European Commission Approval for QALSODY (tofersen), a Novel Therapy for a Rare Genetic Form of ALS | EMA Drug Approvals | 2024 | iPharmaCenter

ipharmaservices

May 31, 2024

EMA Drug Approvals | Europe drug approvals | 2024 | iPharmaCenter

ipharmaservices

Apr 23, 2024

EMA Drug Approvals - CHMP Positive Opinions | March 2024 | iPharmaCenter

ipharmaservices

Mar 24, 2024

CHMP Positive Opinions | February | 2024 | iPharmaCenter

ipharmaservices

Feb 28, 2024